{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:39:31Z","timestamp":1794278371266,"version":"4.9.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T00:00:00Z","timestamp":1621209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T00:00:00Z","timestamp":1621209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cancer cachexia worsens the treatment outcomes of patients with small-cell lung cancer (SCLC). However, no reliable biomarker of cancer cachexia is yet known.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively evaluated male SCLC patients who received induction chemotherapy or concurrent chemoradiotherapy. The cachexia index (CXI) was calculated as skeletal muscle index \u00d7 serum albumin level (g\/dL)\/neutrophil-to-lymphocyte ratio. The CXI cutoff according to tumor stage was determined based on a time-dependent receiver operating characteristic curve, and all patients were divided into low- and high-CXI groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 267 patients, 83 and 24 patients with limited-stage disease (LD) and 123 and 37 patients with extensive-stage disease (ED) were assigned to the high- and low-CXI groups, respectively. Only one of 24 patients (4.2%) with LD in the low-CXI group achieved a complete response (CR), whereas 30 of 83 patients (36.1%) with LD in the high-CXI group achieved CRs (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004). More low-CXI patients required early discontinuation of treatment because of treatment-related toxicity compared to the high-CXI patients (37.5% vs. 16.9%, respectively,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.030, for LD patients; 27.0% vs. 11.4%, respectively,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.019, for ED patients). The median progression-free survival (PFS) and overall survival (OS) were significantly shorter in the low-CXI group than the high-CXI group (6.3 vs. 11.1\u2009months and 7.5 vs. 20.6\u2009months, respectively, both\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009\u00a00.001 for LD patients; 2.9 vs. 6.3\u2009months and 5.8 vs. 12.8\u2009months, respectively, both\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009\u00a00.001, for ED patients). On multivariate analysis, low-CXI status was an independent poor prognostic factor for both PFS and OS regardless of the tumor stage.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A low CXI was associated with treatment intolerance, poor treatment response rate, and poor prognosis in SCLC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-021-08300-x","type":"journal-article","created":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T09:02:54Z","timestamp":1621242174000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Clinical significance of the cachexia index in patients with small cell lung cancer"],"prefix":"10.1186","volume":"21","author":[{"given":"Se-Il","family":"Go","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Jung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyeong-Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,17]]},"reference":[{"issue":"12","key":"8300_CR1","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/nrc.2017.87","volume":"17","author":"AF Gazdar","year":"2017","unstructured":"Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer. 2017;17(12):725\u201337. https:\/\/doi.org\/10.1038\/nrc.2017.87.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"8300_CR2","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nrclinonc.2017.71","volume":"14","author":"JK Sabari","year":"2017","unstructured":"Sabari JK, Lok BH, Laird JH, Poirier JT, Rudin CM. Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol. 2017;14(9):549\u201361. https:\/\/doi.org\/10.1038\/nrclinonc.2017.71.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"8300_CR3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1056\/NEJMoa003034","volume":"346","author":"K Noda","year":"2002","unstructured":"Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346(2):85\u201391. https:\/\/doi.org\/10.1056\/NEJMoa003034.","journal-title":"N Engl J Med"},{"issue":"1","key":"8300_CR4","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/S1470-2045(13)70511-4","volume":"15","author":"K Kubota","year":"2014","unstructured":"Kubota K, Hida T, Ishikura S, Mizusawa J, Nishio M, Kawahara M, et al. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study. Lancet Oncol. 2014;15(1):106\u201313. https:\/\/doi.org\/10.1016\/S1470-2045(13)70511-4.","journal-title":"Lancet Oncol"},{"issue":"1","key":"8300_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.4143\/crt.2018.019","volume":"51","author":"DW Kim","year":"2019","unstructured":"Kim DW, Kim HG, Kim JH, Park K, Kim HK, Jang JS, et al. Randomized phase III trial of Irinotecan plus Cisplatin versus Etoposide plus Cisplatin in chemotherapy-naive Korean patients with extensive-disease small cell lung Cancer. Cancer Res Treat. 2019;51(1):119\u201327. https:\/\/doi.org\/10.4143\/crt.2018.019.","journal-title":"Cancer Res Treat"},{"issue":"23","key":"8300_CR6","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szczesna A, et al. First-line Atezolizumab plus chemotherapy in extensive-stage small-cell lung Cancer. N Engl J Med. 2018;379(23):2220\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1809064.","journal-title":"N Engl J Med"},{"issue":"10212","key":"8300_CR7","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(19)32222-6.","journal-title":"Lancet."},{"issue":"1","key":"8300_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jtho.2018.09.027","volume":"14","author":"M Christodoulou","year":"2019","unstructured":"Christodoulou M, Blackhall F, Mistry H, Leylek A, Knegjens J, Remouchamps V, et al. Compliance and outcome of elderly patients treated in the concurrent once-daily versus twice-daily radiotherapy (CONVERT) trial. J Thorac Oncol. 2019;14(1):63\u201371. https:\/\/doi.org\/10.1016\/j.jtho.2018.09.027.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"8300_CR9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.cllc.2019.05.007","volume":"20","author":"SE Schild","year":"2019","unstructured":"Schild SE, Zhao L, Wampfler JA, Daniels TB, Sio T, Ross HJ, et al. Small-cell lung Cancer in very elderly (>\/= 80 years) patients. Clin Lung Cancer. 2019;20(4):313\u201321. https:\/\/doi.org\/10.1016\/j.cllc.2019.05.007.","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"8300_CR10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jgo.2013.07.008","volume":"5","author":"ML Janssen-Heijnen","year":"2014","unstructured":"Janssen-Heijnen ML, Maas HA, Koning CC, van der Bruggen-Bogaarts BA, Groen HJ, Wymenga AN. Tolerance and benefits of treatment for elderly patients with limited small-cell lung cancer. J Geriatr Oncol. 2014;5(1):71\u20137. https:\/\/doi.org\/10.1016\/j.jgo.2013.07.008.","journal-title":"J Geriatr Oncol"},{"issue":"5","key":"8300_CR11","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489\u201395. https:\/\/doi.org\/10.1016\/S1470-2045(10)70218-7.","journal-title":"Lancet Oncol"},{"issue":"2","key":"8300_CR12","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/jcsm.12391","volume":"10","author":"IMG da Rocha","year":"2019","unstructured":"da Rocha IMG, Marcadenti A, de Medeiros GOC, et al. Is cachexia associated with chemotherapy toxicities in gastrointestinal cancer patients? A prospective study. J Cachexia Sarcopenia Muscle. 2019;10(2):445\u201354. https:\/\/doi.org\/10.1002\/jcsm.12391.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"1","key":"8300_CR13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.21037\/apm.2018.08.04","volume":"8","author":"P Kasvis","year":"2019","unstructured":"Kasvis P, Vigano M, Vigano A. Health-related quality of life across cancer cachexia stages. Ann Palliat Med. 2019;8(1):33\u201342. https:\/\/doi.org\/10.21037\/apm.2018.08.04.","journal-title":"Ann Palliat Med"},{"issue":"12","key":"8300_CR14","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1200\/JCO.2012.45.2722","volume":"31","author":"L Martin","year":"2013","unstructured":"Martin L, Birdsell L, Macdonald N, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31(12):1539\u201347. https:\/\/doi.org\/10.1200\/JCO.2012.45.2722.","journal-title":"J Clin Oncol"},{"issue":"3","key":"8300_CR15","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0169-5002(02)00508-1","volume":"39","author":"RM Bremnes","year":"2003","unstructured":"Bremnes RM, Sundstrom S, Aasebo U, et al. The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer. 2003;39(3):303\u201313. https:\/\/doi.org\/10.1016\/S0169-5002(02)00508-1.","journal-title":"Lung Cancer"},{"issue":"10","key":"8300_CR16","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1038\/bjc.1996.606","volume":"74","author":"J Bernhard","year":"1996","unstructured":"Bernhard J, Hurny C, Bacchi M, et al. Initial prognostic factors in small-cell lung cancer patients predicting quality of life during chemotherapy. Swiss Group for Clinical Cancer Research (SAKK). Br J Cancer. 1996;74(10):1660\u20137. https:\/\/doi.org\/10.1038\/bjc.1996.606.","journal-title":"Br J Cancer"},{"issue":"6B","key":"8300_CR17","first-page":"3749","volume":"22","author":"C Christodolou","year":"2002","unstructured":"Christodolou C, Pavlidis N, Samantas E, Fountzilas G, Kouvatseas G, Pagdatoglou K, et al. Prognostic factors in Greek patients with small cell lung cancer (SCLC). A Hellenic cooperative oncology group study. Anticancer Res. 2002;22(6B):3749\u201357.","journal-title":"Anticancer Res"},{"issue":"12","key":"8300_CR18","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1097\/JTO.0000000000000690","volume":"10","author":"EY Kim","year":"2015","unstructured":"Kim EY, Kim YS, Park I, Ahn HK, Cho EK, Jeong YM. Prognostic significance of CT-determined sarcopenia in patients with small-cell lung Cancer. J Thorac Oncol. 2015;10(12):1795\u20139. https:\/\/doi.org\/10.1097\/JTO.0000000000000690.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"8300_CR19","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1007\/s00520-015-2997-x","volume":"24","author":"SI Go","year":"2016","unstructured":"Go SI, Park MJ, Song HN, Kang MH, Park HJ, Jeon KN, et al. Sarcopenia and inflammation are independent predictors of survival in male patients newly diagnosed with small cell lung cancer. Support Care Cancer. 2016;24(5):2075\u201384. https:\/\/doi.org\/10.1007\/s00520-015-2997-x.","journal-title":"Support Care Cancer"},{"key":"8300_CR20","doi-asserted-by":"publisher","unstructured":"Kim EY, Lee HY, Kim YS, et al. Prognostic significance of cachexia score assessed by CT in male patients with small cell lung cancer. Eur J Cancer Care (Engl). 2018;27(1):e12695. https:\/\/doi.org\/10.1111\/ecc.12695.","DOI":"10.1111\/ecc.12695"},{"issue":"11","key":"8300_CR21","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1111\/1759-7714.12862","volume":"9","author":"SI Go","year":"2018","unstructured":"Go SI, Jeon H, Park SW, Kang MH, Kim HG, Lee GW. Low pre-treatment nutritional index is significantly related to poor outcomes in small cell lung cancer. Thorac Cancer. 2018;9(11):1483\u201391. https:\/\/doi.org\/10.1111\/1759-7714.12862.","journal-title":"Thorac Cancer"},{"issue":"1","key":"8300_CR22","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/1759-7714.13229","volume":"11","author":"GW Lee","year":"2020","unstructured":"Lee GW, Go SI, Kim DW, Kim HG, Kim JH, An HJ, et al. Geriatric nutritional risk index as a prognostic marker in patients with extensive-stage disease small cell lung cancer: results from a randomized controlled trial. Thorac Cancer. 2020;11(1):62\u201371. https:\/\/doi.org\/10.1111\/1759-7714.13229.","journal-title":"Thorac Cancer"},{"key":"8300_CR23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.4137\/CMO.S30891","volume":"9","author":"SH Jafri","year":"2015","unstructured":"Jafri SH, Previgliano C, Khandelwal K, Shi R. Cachexia index in advanced non-small-cell lung Cancer patients. Clin Med Insights Oncol. 2015;9:87\u201393. https:\/\/doi.org\/10.4137\/CMO.S30891.","journal-title":"Clin Med Insights Oncol"},{"issue":"6","key":"8300_CR24","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00277-017-2958-1","volume":"96","author":"R Karmali","year":"2017","unstructured":"Karmali R, Alrifai T, Fughhi IAM, Ng R, Chukkapalli V, Shah P, et al. Impact of cachexia on outcomes in aggressive lymphomas. Ann Hematol. 2017;96(6):951\u20136. https:\/\/doi.org\/10.1007\/s00277-017-2958-1.","journal-title":"Ann Hematol"},{"issue":"2","key":"8300_CR25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"issue":"1","key":"8300_CR26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12874-017-0332-6","volume":"17","author":"AN Kamarudin","year":"2017","unstructured":"Kamarudin AN, Cox T, Kolamunnage-Dona R. Time-dependent ROC curve analysis in medical research: current methods and applications. BMC Med Res Methodol. 2017;17(1):53. https:\/\/doi.org\/10.1186\/s12874-017-0332-6.","journal-title":"BMC Med Res Methodol"},{"issue":"9","key":"8300_CR27","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1200\/JCO.1999.17.9.2681","volume":"17","author":"JA Bonner","year":"1999","unstructured":"Bonner JA, Sloan JA, Shanahan TG, Brooks BJ, Marks RS, Krook JE, et al. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol. 1999;17(9):2681\u201391. https:\/\/doi.org\/10.1200\/JCO.1999.17.9.2681.","journal-title":"J Clin Oncol"},{"issue":"36","key":"8300_CR28","doi-asserted-by":"publisher","first-page":"4240","DOI":"10.1200\/JCO.2015.62.4270","volume":"33","author":"CD Corso","year":"2015","unstructured":"Corso CD, Rutter CE, Park HS, Lester-Coll NH, Kim AW, Wilson LD, et al. Role of Chemoradiotherapy in elderly patients with limited-stage small-cell lung Cancer. J Clin Oncol. 2015;33(36):4240\u20136. https:\/\/doi.org\/10.1200\/JCO.2015.62.4270.","journal-title":"J Clin Oncol"},{"issue":"8","key":"8300_CR29","doi-asserted-by":"publisher","first-page":"e0161125","DOI":"10.1371\/journal.pone.0161125","volume":"11","author":"EY Kim","year":"2016","unstructured":"Kim EY, Kim YS, Seo JY, Park I, Ahn HK, Jeong YM, et al. The relationship between sarcopenia and systemic inflammatory response for Cancer Cachexia in small cell lung Cancer. PLoS One. 2016;11(8):e0161125. https:\/\/doi.org\/10.1371\/journal.pone.0161125.","journal-title":"PLoS One"},{"issue":"1","key":"8300_CR30","doi-asserted-by":"publisher","first-page":"10481","DOI":"10.1038\/srep10481","volume":"5","author":"T Zhou","year":"2015","unstructured":"Zhou T, Zhan J, Hong S, Hu Z, Fang W, Qin T, et al. Ratio of C-reactive protein\/albumin is an inflammatory prognostic score for predicting overall survival of patients with small-cell lung Cancer. Sci Rep. 2015;5(1):10481. https:\/\/doi.org\/10.1038\/srep10481.","journal-title":"Sci Rep"},{"issue":"10","key":"8300_CR31","doi-asserted-by":"publisher","first-page":"e0164056","DOI":"10.1371\/journal.pone.0164056","volume":"11","author":"EY Kim","year":"2016","unstructured":"Kim EY, Kim N, Kim YS, Seo JY, Park I, Ahn HK, et al. Prognostic significance of modified advanced lung Cancer inflammation index (ALI) in patients with small cell lung Cancer_ comparison with original ALI. PLoS One. 2016;11(10):e0164056. https:\/\/doi.org\/10.1371\/journal.pone.0164056.","journal-title":"PLoS One"},{"issue":"1","key":"8300_CR32","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3892\/mco.2017.1261","volume":"7","author":"K Kurishima","year":"2017","unstructured":"Kurishima K, Watanabe H, Ishikawa H, Satoh H, Hizawa N. Modified Glasgow prognostic score in patients with small-cell lung cancer. Mol Clin Oncol. 2017;7(1):121\u20134. https:\/\/doi.org\/10.3892\/mco.2017.1261.","journal-title":"Mol Clin Oncol"},{"issue":"3","key":"8300_CR33","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bjc.2014.317","volume":"111","author":"MH Kang","year":"2014","unstructured":"Kang MH, Go SI, Song HN, Lee A, Kim SH, Kang JH, et al. The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer. Br J Cancer. 2014;111(3):452\u201360. https:\/\/doi.org\/10.1038\/bjc.2014.317.","journal-title":"Br J Cancer"},{"issue":"10","key":"8300_CR34","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1007\/s12094-015-1289-8","volume":"17","author":"N Shao","year":"2015","unstructured":"Shao N, Cai Q. High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer. Clin Transl Oncol. 2015;17(10):772\u20138. https:\/\/doi.org\/10.1007\/s12094-015-1289-8.","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"8300_CR35","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1186\/s12885-017-3893-1","volume":"17","author":"D Liu","year":"2017","unstructured":"Liu D, Huang Y, Li L, Song J, Zhang L, Li W. High neutrophil-to-lymphocyte ratios confer poor prognoses in patients with small cell lung cancer. BMC Cancer. 2017;17(1):882. https:\/\/doi.org\/10.1186\/s12885-017-3893-1.","journal-title":"BMC Cancer"},{"issue":"1","key":"8300_CR36","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1200\/JCO.2014.56.1894","volume":"33","author":"L Martin","year":"2015","unstructured":"Martin L, Senesse P, Gioulbasanis I, Antoun S, Bozzetti F, Deans C, et al. Diagnostic criteria for the classification of cancer-associated weight loss. J Clin Oncol. 2015;33(1):90\u20139. https:\/\/doi.org\/10.1200\/JCO.2014.56.1894.","journal-title":"J Clin Oncol"},{"issue":"2","key":"8300_CR37","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1017\/S0029665115004279","volume":"75","author":"CM Prado","year":"2016","unstructured":"Prado CM, Cushen SJ, Orsso CE, Ryan AM. Sarcopenia and cachexia in the era of obesity: clinical and nutritional impact. Proc Nutr Soc. 2016;75(2):188\u201398. https:\/\/doi.org\/10.1017\/S0029665115004279.","journal-title":"Proc Nutr Soc"},{"key":"8300_CR38","doi-asserted-by":"publisher","unstructured":"Hou YC, Wang CJ, Chao YJ, et al. Elevated Serum Interleukin-8 Level Correlates with Cancer-Related Cachexia and Sarcopenia: An Indicator for Pancreatic Cancer Outcomes. J Clin Med. 2018;7(12):502. https:\/\/doi.org\/10.3390\/jcm7120502.","DOI":"10.3390\/jcm7120502"},{"key":"8300_CR39","doi-asserted-by":"publisher","first-page":"2063179","DOI":"10.1155\/2018\/2063179","volume":"2018","author":"J Abrigo","year":"2018","unstructured":"Abrigo J, Elorza AA, Riedel CA, et al. Role of oxidative stress as key regulator of muscle wasting during Cachexia. Oxidative Med Cell Longev. 2018;2018:2063179.","journal-title":"Oxidative Med Cell Longev"},{"issue":"4","key":"8300_CR40","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/SPC.0000000000000091","volume":"8","author":"AA Narsale","year":"2014","unstructured":"Narsale AA, Carson JA. Role of interleukin-6 in cachexia: therapeutic implications. Curr Opin Support Palliat Care. 2014;8(4):321\u20137. https:\/\/doi.org\/10.1097\/SPC.0000000000000091.","journal-title":"Curr Opin Support Palliat Care"},{"issue":"1","key":"8300_CR41","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1172\/JCI114419","volume":"85","author":"DA Brenner","year":"1990","unstructured":"Brenner DA, Buck M, Feitelberg SP, Chojkier M. Tumor necrosis factor-alpha inhibits albumin gene expression in a murine model of cachexia. J Clin Invest. 1990;85(1):248\u201355. https:\/\/doi.org\/10.1172\/JCI114419.","journal-title":"J Clin Invest"},{"issue":"2","key":"8300_CR42","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1634\/theoncologist.2019-0289","volume":"25","author":"R Jain","year":"2020","unstructured":"Jain R, Handorf E, Khare V, Blau M, Chertock Y, Hall MJ. Impact of baseline nutrition and exercise status on toxicity and outcomes in phase I and II oncology clinical trial participants. Oncologist. 2020;25(2):161\u20139. https:\/\/doi.org\/10.1634\/theoncologist.2019-0289.","journal-title":"Oncologist."},{"issue":"11","key":"8300_CR43","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1158\/1078-0432.CCR-06-3067","volume":"13","author":"CM Prado","year":"2007","unstructured":"Prado CM, Baracos VE, McCargar LJ, et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res. 2007;13(11):3264\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-3067.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"8300_CR44","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1158\/1078-0432.CCR-08-2242","volume":"15","author":"CM Prado","year":"2009","unstructured":"Prado CM, Baracos VE, McCargar LJ, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009;15(8):2920\u20136. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-2242.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"8300_CR45","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1200\/JCO.2009.24.9730","volume":"28","author":"S Antoun","year":"2010","unstructured":"Antoun S, Birdsell L, Sawyer MB, Venner P, Escudier B, Baracos VE. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol. 2010;28(6):1054\u201360. https:\/\/doi.org\/10.1200\/JCO.2009.24.9730.","journal-title":"J Clin Oncol"},{"issue":"3","key":"8300_CR46","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ejso.2014.11.040","volume":"41","author":"BH Tan","year":"2015","unstructured":"Tan BH, Brammer K, Randhawa N, et al. Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer. Eur J Surg Oncol. 2015;41(3):333\u20138. https:\/\/doi.org\/10.1016\/j.ejso.2014.11.040.","journal-title":"Eur J Surg Oncol"},{"issue":"11","key":"8300_CR47","doi-asserted-by":"publisher","first-page":"4721","DOI":"10.1007\/s00520-016-3321-0","volume":"24","author":"EY Kim","year":"2016","unstructured":"Kim EY, Kim YS, Park I, Ahn HK, Cho EK, Jeong YM, et al. Evaluation of sarcopenia in small-cell lung cancer patients by routine chest CT. Support Care Cancer. 2016;24(11):4721\u20136. https:\/\/doi.org\/10.1007\/s00520-016-3321-0.","journal-title":"Support Care Cancer"},{"issue":"29","key":"8300_CR48","doi-asserted-by":"publisher","first-page":"47007","DOI":"10.18632\/oncotarget.16552","volume":"8","author":"SI Go","year":"2017","unstructured":"Go SI, Park MJ, Song HN, Kim HG, Kang MH, Kang JH, et al. A comparison of pectoralis versus lumbar skeletal muscle indices for defining sarcopenia in diffuse large B-cell lymphoma - two are better than one. Oncotarget. 2017;8(29):47007\u201319. https:\/\/doi.org\/10.18632\/oncotarget.16552.","journal-title":"Oncotarget."},{"issue":"1","key":"8300_CR49","doi-asserted-by":"publisher","first-page":"11369","DOI":"10.1038\/s41598-018-29825-5","volume":"8","author":"BA Derstine","year":"2018","unstructured":"Derstine BA, Holcombe SA, Ross BE, Wang NC, Su GL, Wang SC. Skeletal muscle cutoff values for sarcopenia diagnosis using T10 to L5 measurements in a healthy US population. Sci Rep. 2018;8(1):11369. https:\/\/doi.org\/10.1038\/s41598-018-29825-5.","journal-title":"Sci Rep"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08300-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08300-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08300-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T09:04:50Z","timestamp":1621242290000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08300-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,17]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8300"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08300-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,17]]},"assertion":[{"value":"2 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of Gyeongsang National University Hospital and conducted in accordance with the Good Clinical Practice guidelines and the Declaration of Helsinki. The informed consent was waived by the Institutional Review Board of Gyeongsang National University Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"563"}}